Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | LTA4H | P09960 | 9/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502865 | 0.86 | MEN1 (0.58) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL2170643 | 0.85 | LTA4H (0.76) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL23273969 | 0.85 | LTA4H (0.65) | RAB9ALTA4HMEN1KMT2A | |
| SCHEMBL3505091 | 0.84 | MAOB (0.60) | RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3505916 | 0.84 | LTA4H (0.78) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL10118238 | 0.84 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL21067416 | 0.84 | LTA4H (1.00) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL23636399 | 0.83 | LTA4H (0.68) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL4337603 | 0.83 | MAOB (0.59) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL5659338 | 0.82 | LTA4H (0.76) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | claimed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| CN-100482638-C | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| CN-1656057-A | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | RAB9A 2591/4885SMN1; SMN2 933/4885NPC1 392/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | RAB9A 3058/4885SMN1; SMN2 3684/4885NPC1 738/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | RAB9A 2429/4885SMN1; SMN2 950/4885NPC1 436/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | RAB9A 2328/4885SMN1; SMN2 904/4885NPC1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.